CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Services-Commercial Physical & Biological Research
- Revenue
- $4.0B
- 0.9% YoY
- Operating margin
- 0.6%
- 89% YoY
- EBITDA
- $428M
- 27% YoY
- Market cap
- $17.2B
- Employees
- 19,700
- $204K revenue each
- Net debt / EBITDA
- 5.7×
- $2.4B net debt
- AI in 10-K
- 1.9
- mentions per 10K words
Takeover score 3 of 13
Fixable underperformance 1 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo2% of revenueOver 10% of revenue
- Payouts exceed cash flowNo49% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyYes41% of assetsOver 40% of assets
- Shareholder dissentNo94% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeYes$204K · 20th pctBottom quartile of its SIC industry
- Quiet on AINo1.9 per 10K words · 53rd pctBottom quartile of AI mentions in 10-Ks
- Net cashNo5.7× EBITDA net debtMore cash than debt, positive EBITDA
- Buyout-sizedNo$17.2B market capMarket cap $500M–$5B
Catalysts 1 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingYes−$52M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B | 0.9% |
| Operating income | $590M | $651M | $617M | $227M | $25M | 89% |
| Net income | $391M | $486M | $475M | $22M | −$144M | 750% |
| Operating cash flow | $761M | $620M | $684M | $735M | $738M | 0.4% |
| Capex | $229M | $325M | $319M | $233M | $219M | 5.9% |
| Stock-based comp | $71M | $74M | $72M | $70M | $71M | 1.7% |
| Buybacks | $41M | $39M | $24M | $119M | $361M | 203% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $7K · 2
- Open-market sells, 12 mo
- $52M · 21
- Net
- −$52M
Pay vs performance
No pay-versus-performance disclosure yet.